



## Supplementary Information for

### Weevil *pgrp-lb* prevents endosymbiont TCT dissemination and chronic host systemic immune activation

Justin Maire, Carole Vincent-Monégat, Séverine Balmand, Agnès Vallier, Mireille Hervé, Florent Masson, Nicolas Parisot, Aurélien Vigneron, Caroline Anselme, Jackie Perrin, Julien Orlans, Isabelle Rahiouï, Pedro Da Silva, Marie-Odile Fauvarque, Dominique Mengin-Lecreux, Anna Zaidman-Rémy\*, Abdelaziz Heddi\*

Paste corresponding author name here: Abdelaziz Heddi and Anna Zaidman-Rémy  
[abdelaziz.heddi@insa-lyon.fr](mailto:abdelaziz.heddi@insa-lyon.fr) (A.H.), [anna.zaidman@insa-lyon.fr](mailto:anna.zaidman@insa-lyon.fr) (A.Z.-R.).

#### This PDF file includes:

- Supplementary Material and Methods
- Figs. S1 to S7
- Tables S1 to S3
- Supplementary sequences
- References for SI reference citations

#### Other supplementary materials for this manuscript include the following:

## **Supplementary Information Text**

### **Supplementary Material and Methods**

#### **Multiple sequence alignments**

Multiple sequence alignments were performed using the Clustal Omega program [1]. Uniprot accession numbers are as follows: *Sodalis pierantonius* MurE: W0HJN2; *Escherichia coli* MurE: P22188; *Bacillus subtilis* MurE: Q03523; *Helicobacter pylori* MurE: E1S713; *Pseudomonas aeruginosa* MurE: A0A0F6UH44; *Vibrio cholera* MurE: Q9X6N4; *Staphylococcus aureus*: Q2FZP6 MurE; *Streptococcus pneumonia* MurE: A0A0E8T7T8; *Enterococcus faecalis* MurE: Q838A4; *Glossina morsitans* PGRP-LB: A0A1B0G8B0; *Drosophila melanogaster* PGRP-LB: Q8INK6; *Euprymna scolopes* PGRP2: Q32S45; *Drosophila melanogaster* PGRP-LCx: Q9GNK5-2; *Drosophila melanogaster* PGRP-SA: Q9VYX7; *Homo sapiens* PGLYRP1: O75594; *Homo sapiens* PGLYRP3: Q96LB9.

#### ***S. pierantonius* PG analysis**

300 bacteriomes from *S. zeamais* fourth instar larvae were dissected. This material was resuspended into 500 µl of 4.5% SDS solution at 95–100°C and extraction was continued for one hour at this temperature under agitation. PG-containing pellets were recovered by centrifugation at 200,000 g for 30 min at room temperature with a Beckman TL-100 centrifuge and they were subsequently washed several times with water. The final pellets were resuspended in 400 µL of 6 M HCl and hydrolysis was performed for 16 h at 96°C. The amino acid and hexosamine composition of hydrolysates was then analyzed with a Hitachi L8800 amino acid analyzer (ScienceTec).

#### **Sample Preparation for Histology**

Samples were fixed in PFA 4%. After one week at 4°C, the fixative was replaced by several washings with PBS before embedding the tissue in 1.3% agar. Subsequently, samples were dehydrated through a graded ethanol (EtOH) series and transferred to butanol-1, at 4°C, overnight. Samples in agar were then embedded in melted Paraplast. Tissue sections (3 µm thick) were cut using an HM 340 E electronic rotary microtome (ThermoFisher Scientific). Sections were placed on poly-lysine-coated slides, dried overnight in a 37°C oven, and stored at 4°C prior to further treatments.

#### **PGRP-LB Immunostaining**

Paraffin sections were dewaxed twice in methylcyclohexane for 10 min, rinsed in EtOH 100°, and rehydrated through an ethanol gradient to PBS. Slides were incubated with 1% Bovine Serum Albumine (BSA) in PBS for 30 min prior to primary antibody incubation, overnight at 4°C. Rabbit polyclonal anti-serum directed against PGRP-LB (anti-PGRP-LB antibody, used in Vallier et al., 2009) was used as the primary antibody. Preimmune rabbit serum (J0) was used as a negative control. Antibody specificity was checked by western blot [2] and immunostainings

(Figure S7B) on RNAi *pgrp-lb* individuals. All antisera were diluted at 1:500 in PBS containing 0.1% BSA. After primary antiserum incubation, sections were washed with PBS containing 0.2% Tween. Primary antibodies were detected with fluorescent donkey anti-rabbit IgG, labeled with Alexa Fluor 488. This secondary antibody was applied for 1 h at room temperature, diluted at 1:600 in 0.1% BSA in PBS. They were washed with PBS-Tween, rinsed with PBS and washed several times with tap water. Sections were then dried and mounted using PermaFluorTM Aqueous Mounting Medium (ThermoFisher Scientific), together with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for nuclear staining (3 µg/ml of medium). Images were acquired using an epifluorescence microscope (Olympus IX81), under specific emission filters: HQ535/50 for the green signal (antibody staining), D470/40 for the blue signal (DAPI) and HQ610/75 for the red signal (unspecific autofluorescence from tissue). Images were captured using an XM10 camera and the CellSens Software (Soft Imaging System). Images were treated using ImageJ (release 1.47v). For image treatment, each color channel was treated independently.

#### **RNA isolation and libraries construction for RNA-seq**

For *S. oryzae*, RNA-seq datasets were retrieved from the Sequence Read Archive (SRX1034967-SRX1034972 and SRX3721133-SRX3721138). RNA-seq libraries for two other species, *S. zeamais* and *S. linearis* were constructed from a mix of two different pools of adult weevils, naïve and challenged with Gram-positive (*M. luteus*, strain CCM169) or Gram-negative (*D. dadantii*, strain A470) bacteria. Five individuals were randomly sampled at 6 h and 12 h post-injection for each bacterial challenge leading to a total of 20 adults per weevil species. Total RNA from these 20 adults was extracted with Trizol reagent (ThermoFisher Scientific) following the manufacturer's instructions. RNA was incubated with 1 U/µg of RQ1 RNase-free DNase (Promega) for 30 min, at 37°C then purified with the NucleoSpin RNA Clean-up kit (Macherey-Nagel). Total RNA concentration and quality were checked using the Qubit Fluorometer (ThermoFisher Scientific) and the Agilent 2200 TapeStation (Agilent Technologies). 20 naïve adults were randomly selected for *S. zeamais* and *S. linearis* weevil species and total RNA was extracted using the same procedure. Two different pools were prepared for the two weevil species respectively, by mixing 1 µg of RNA from naïve weevils with 1 µg of RNA from weevils challenged with bacteria. RNA-seq libraries were then prepared using the SENSE mRNA-seq library preparation kit (Lexogen) following the manufacturer's instructions and sequenced on an Illumina NextSeq500 platform (2x150bp, Illumina) at the sequencing platform of the IGFL (Institut de Génomique Fonctionnelle de Lyon, Ecole Normale Supérieure de Lyon, France).

#### **Transcriptome assembly and identification of PGRP-LB transcripts**

The raw reads were first processed using cutadapt v1.16 [3] to remove adapters and trim low-quality ends (Q < 20). Transcriptome assembly was performed using Trinity v2.3.2 [4] for each weevil species. *pgrp-lb* transcripts were identified using TBLASTN [5] with the *D. melanogaster* PGRP-LB protein sequence (Uniprot: Q8INK6) as query. All data from this study have been deposited at the NCBI Sequence Read Archive (SRA) under the following accession numbers: *S. zeamais*: SRP149413; *S. linearis*: SRP149424.

#### **PCR amplification of *pgrp-lb* transcripts**

PCR amplification of *pgrp-lb* transcripts was performed with a Taq'ozyme kit (Ozyme) on total cDNA from *S. zeamais* (bacteriome extracts for *pgrp-lbi* and *pgrp-lbt*, challenged whole larvae for *pgrp-lbe*). Primers used are listed in **Table S3**. 1% agarose gel electrophoresis was then performed in order to visualize the amplified fragments.

### PGRP-LBi production and purification

PGRP-LBi was expressed, produced and purified in *E. coli* as previously described [2], and used for antibody production, biochemical assays, and bactericidal activity. The purified protein was concentrated and buffer-exchanged in Amicon Ultra 10K centrifugal filters from Merck Millipore:

- to buffer containing 0.05 M Tris-HCl (pH 8.8), 1 mM EDTA and 10% glycerol for antibody preparation.
- to buffer containing 0.02 M HEPES pH 7.4, 2 mM ZnSO<sub>4</sub>, 4 mM 2-mercaptoethanol and 10% glycerol for enzymatic activity assay and bactericidal activity assay.

### DNA constructions for *pgrp-lb* expression in S2 *Drosophila* cells

*pgrp-lbi* was amplified from *S. zeamais* cDNA by PCR using the primers pgrp-lbi-S2-EcoRI-for and pgrp-lbi-S2-EcoRV-rev, containing respectively EcoRI and EcoRV restriction sites. The PCR product was then inserted into the EcoRI and EcoRV sites of a pMT-V5-HisA plasmid (ThermoFisher Scientific) to produce pMT\_*pgrp-lbi*\_V5-His. This construct was used to produce a V5 C-terminally tagged PGRP-LBi (Construction (i), **Figure S3A**).

*pgrp-lbt* was amplified from *S. zeamais* cDNA by PCR using the primers pgrp-lbt-S2-EcoRV-for and pgrp-lbt-S2-XhoI-rev, containing respectively EcoRV and XhoI restriction sites. The PCR product was then inserted into the EcoRV and XhoI sites of a pMT-V5-HisA plasmid (ThermoFisher Scientific) to produce pMT\_*pgrp-lbt*\_V5-His. This construct was used to produce a C-terminally V5 tagged PGRP-LBt (Construction (ii), **Figure S3A**).

The *egfp* gene coding sequence was amplified from pEGFP-C1 (Clontech) by PCR using the primers Fw\_EGFP\_KpnI and Rv\_EGFP\_EcoV and the product was inserted into the KpnI and EcoRV site of plasmid pMT\_*pgrp-lbt*\_V5-His to produce pEGFP\_*pgrp-lbt*\_V5-His. This construct was used to produce an N-terminally EGFP and V5 C-terminally tagged PGRP-LBt (Construction (iii), **Figure S3A**).

All constructs were verified by DNA sequencing, and constructions were then used for ectopic expression in S2 *Drosophila* cells. All the primers used are listed in **Table S3**.

### *pgrp-lb* expression in S2 *Drosophila* cells and immunostainings

S2 cells were thawed and put in culture in Schneider medium (Invitrogen) containing fetal bovine serum (FBS, Fisher Scientific) 10% and penicillin-streptomycin 1% (Euromedex). 8-well Nunc® Lab-Tek® Chamber Slide™ systems (Sigma-Aldrich) were filled with 500 µL of S2 cells at 10<sup>6</sup> cells/mL. Cell transfection was performed by adding in each well: 100µL Schneider medium, 4 µL transfectin, 100 ng of construction (i), (ii) or (iii), and 350 µL Schneider medium containing FBS 10% and penicillin-streptomycin 1%. The day after, plasmid expression was induced by adding 2.5 µL of CuSO<sub>4</sub> 100mM in each well. Immunostainings were performed two days later. Cells were fixed with 500 µL PFA 4% during 10 min, washed repeatedly with PBS, permeabilized with PBS + triton 0.2% for 5 min. After washing with PBS, wells were blocked

with 500 µL PBS + goat serum 5% (Sigma-Aldrich) for 1h, and rinsed with PBS. Wells were incubated with primary antibodies for 3 hours at room temperature (mouse anti-V5 antibody diluted 1:500, or rabbit anti-EGFP antibody diluted 1:200, Fisher Scientific). Wells were washed with PBS and incubated for 2 h at room temperature with secondary antibodies (Alexa Fluor® 647 goat anti-mouse IgG diluted 1:5000, ThermoFisher Scientific, or Rhodamine Red™-X goat anti-rabbit IgG, diluted 1:500, Molecular Probes). Wells were washed with PBS, water, and removed from the slide. Slides were dried, and mounted using PermaFluor™ Aqueous Mounting Medium (ThermoFisher Scientific), together with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for nuclear staining (3 µg/ml of medium). Slides were observed with a LSM800 confocal microscope (Zeiss) and images were taken with the Zen software.

#### DNA construction for *pgrp-lbt*-specific dsRNA synthesis

The size of the portion encoding the transmembrane domain (hereafter referred to as ‘TM-domain’), specific to *pgrp-lbt*, is too small (115 bp) to generate a functional dsRNA in order to specifically inhibit *pgrp-lbt* transcripts. To overcome this problem, we generated a repetitive fragment of the cDNA coding for the TM-domain, long enough to trigger the RNAi machinery (194 bp), all the while preserving unique 5' and 3' extremities for PCR amplification with primers 5-pgrp-lbt-T7 and 3-pgrp-lbt-T7. The procedure is illustrated in **Figure S7C**.

First, TM-domain-fragment1 (**Figure S7C**) was amplified from *S. zeamais* total cDNA by PCR with 5\_TM-domain\_F1 and 3\_TM-domain\_F1\_ClaI primers. The fragment 1 (99 bp) was cloned into a pCR2.1-Topo expression vector (Invitrogen). Then, TM-domain-fragment2 (104 bp, **Figure S7C**) was amplified from *S. zeamais* total cDNA by PCR with 5\_TM-domain\_F2\_ClaI and 3\_TM-domain\_F2\_ClaI primers with ClaI SR at each extremities. Finally, pCR2.1-topo-TM-domain-fragment1 and PCR product TM-domain-fragment2 were digested by ClaI, ligated and transformed into an *E. coli* TOP10 strain. The final construction (pCR2.1-topo-TM-domain-fragment1-fragment2) was used as a template for dsRNA synthesis. All constructs were verified by DNA sequencing. All primers used are listed in **Table S3**.

#### DNA Extraction and qPCR Bacterial Count

DNA extraction and symbiont density quantification was performed as previously described [6].

#### *S. pierantonius* localization by Fluorescence *in situ* Hybridization

After methylcyclohexan dewaxing, deproteinization of slides was performed in hydrochlorid acid 0.01 N with pepsin 0.1 mg/mL for 10 min at 37 °C. The sections were then prehybridized, hybridized with a *S. pierantonius* specific 5'-end TAMRA-labeled oligo-probe targeting 16S RNA (TAMRA-ACC-CCC-CTC-TAC-GAG-AC-3', 10 µg/mL), washed and then mounted in PermaFluor Mounting Fluid (ThermoFisher Scientific) containing 3 µg/mL of 4',6-diamidino-2-phenylindole (DAPI), as previously described [7]. Images were acquired the same way as described in the “PGRP-LB immunostaining” part.

#### PGRP-LBi bactericidal assays

*E. coli* (strain MG1655) was grown in LB medium to DO<sub>600</sub>=0.6. In each well of a 96-well plate, 70 µL of bacterial culture were added, as well as 10 µL ethanolamine 0.5 M pH 9.6, 1.25 µL of sterile water or ZnSO<sub>4</sub> 200 mM, and 20 µL of HEPES 20 mM pH 7.4, 2-mercapto-ethanol 4 mM,

glycerol 10% containing PGRP-LBi at concentrations from 0 to 500 µg/mL. A well with sterile LB medium instead of bacteria was included to measure the background signal, and a well containing ampicillin was included as a positive control of a bactericidal activity. Each well was repeated twice in the same plate. The plate was incubated for 18 h at 30°C and DO<sub>600</sub> was then measured in each well with a PowerWave XS plate reader (BioTek).

### Armadillo and Cut immunostainings

Armadillo and Cut localization were performed with the same protocol as the PGRP-LB immunostainings. The anti-Armadillo antibody, developed by E. Wieschaus, and the anti-Cut antibody, developed by G. M. Rubin, were obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. The anti-Armadillo antibody was used at a 1:4 dilution, and the anti-Cut at a 1:10 dilution, as previously described [8]. An Alexa Fluor® 647 goat anti-mouse IgG diluted 1:500 (ThermoFisher Scientific) was used as the secondary antibody in both cases. Images were acquired the same way as described in the “PGRP-LB immunostaining” part.

### Egg count in female ovaries

Following dsRNA injection at day 1 after final ecdysis, female ovaries were dissected from day 4 to day 8, and at day 15 after ecdysis in diethylpyrocarbonate-treated Buffer A (25 mM KCl, 10 mM MgCl<sub>2</sub>, 250 mM Sucrose, 35 mM Tris/HCl, pH=7.5). Eggs were counted in five ovaries by condition.




### Identification of genes of interest and accession numbers

Genes encoding *colA*, *colB*, *sarcotoxin*, *imd*, and *relish* in *S. zeamais* were identified in previous studies [9–11]. *pgrp-lc* was first identified in a previously published *S. oryzae* transcriptome [12], based on the presence of a PG recognition domain, the absence of enzymatic activity, the presence of a RHIM domain and a transmembrane domain. A partial sequence was then recovered in *S. zeamais* based on sequence similarity with *S. oryzae*, and was subsequently amplified and sequenced (accession number: MH423625). *pgrp-lb* transcript sequences were identified from the transcriptomic data published in this study (accession number SRP149413), and were subsequently amplified and sequenced in *S. zeamais*. Accession number are as follows: *pgrp-lbi*: MH423627, *pgrp-lbt*: MH423628, *pgrp-lbe*: MH423629.


### Statistical analysis

Transcriptomic data on immune response kinetics (**Figure 2A**) were analyzed by fitting a Generalized Linear Model (GLM) with a Gamma transformation to the data. The type of PG injected was considered as a 3-level categorical variable representing the injection of sterile PBS (control), TCT, or polymeric DAP-type PG. The time post-infection was considered as a 4-level categorical variable. The impact of TCT or polymeric DAP-type PG was assessed by comparing with a t-test the regression coefficients specific to those factors, with those of PBS injection results. Other transcriptomic data were analyzed doing pairwise comparisons using a Welch t-test on the log-transformed gene expression data. Symbiont quantification data and egg load data were analyzed doing pairwise comparisons using a Student t-test.


All analyses and graphical figures were made using RStudio software v0.98.983 and Hmisc and nlme packages, as well as GraphPad Prism v7 for Windows. The effect of a factor was considered to be significant with a p-value <0.05. Graphical figures represent the mean of all replicates for each point. Error bars represent the standard error calculated as  $\sigma / \sqrt{n}$ , where  $\sigma$  is the standard deviation and n is the number of replicates.




**Figure S1: Peptidoglycan recognition and structure. Related to Figure 2.** **A:** Schematic representation of PGRP-LC, -LE, and -LB function in the IMD pathway activation and regulation by bacterial PG in *Drosophila* [13]. DAP-type PG from Gram-negative bacteria can be monomeric (TCT) or polymeric (see panel B). The transmembrane receptor PGRP-LC recognizes both monomeric and polymeric circulating DAP-type PG. The intracellular isoform of the receptor PGRP-LE can only recognize TCT when located within insect cells. Both receptors lead to the IMD pathway activation, which upregulates AMP-encoding gene expression. PGRP-LB is an amidase that cleaves DAP-type PG into non-immunogenic fragments, therefore inhibiting the IMD pathway. **B:** Structure of DAP-type PG and monomeric fragments used in this study. Chains of DAP-type PG end with a 1,6-anhydro-MurNAc; when released, the terminal disaccharide-tetrapeptide motif corresponds to TCT (in green). Arrows indicate *N*-acetylmuramoyl-L-alanine amidase cleavage sites. **C:** Systemic AMP-encoding gene expression following MurNac-tripeptide-DAP injection. *colA*, *colB* and *sarcotoxin* expression were measured in carcasses by qRT-PCR six hours after either PBS or *E. coli* MurNAc-tripeptide-DAP injections. A.U.: Arbitrary Units. The mean and standard error for five independent replicates are represented. ‘n.s.’ indicates a non-significant difference between two conditions based on a Welch’s t-test. **D:** AMP-encoding gene expression in the bacteriome following *pgrp-lc* inhibition by RNAi. *colA*, *colB* and *sarcotoxin* expression was measured in bacteriomes by qRT-PCR 6 h after either PBS or TCT injection, six days following *gfp* or *pgrp-lc* dsRNA injection. Local AMP expression does not increase following TCT injection when *pgrp-lc* is inhibited. Asterisks indicate a significant difference between two conditions based on a Welch’s t-test. The mean and standard error for five independent replicates are represented. A.U. = Arbitrary Units. n.s.: non-significant; \* p < 0.05; \*\*p < 0.01; \*\*\* p < 0.001.




**Figure S2: PGRP-LB localization in other tissues by immunostaining. Related to Figure 3.**  
 A pre-immune serum was used as the negative control (right column). PGRP-LB-associated signal (white arrowheads) is strongly observed in adult gut bacteriomes (**A**), oocytes and ovarian bacteriomes (**B**). Blue: DAPI; green: PGRP-LB; red: autofluorescence. A scheme showing the adult bacteriome morphology is included (bacteriocytes are in green), highlighting how the section was likely performed and the two caeca (1 and 2) observed in the fluorescence microscopy pictures.




**B** Construction (i) (PGRP-LBi)



**C** Construction (ii) (PGRP-LBt)




**D** Construction (iii) (PGRP-LBt)




**Figure S3: Subcellular localization of PGRP-LBi and PGRP-LBt. Related to Figure 3.** A: Constructions (i), (ii), and (iii) were transfected and expressed in S2 *Drosophila* cells. B-C: Anti-V5 immunostaining, with (right column) or without (left column) membrane permeabilization and observed by confocal microscopy reveals that PGRP-LBi (B) is associated with intracellular signal while PGRP-LBt (C) is associated with transmembrane signal. Scale bar: 6µm. Blue:


DAPI; red: anti-V5 staining. **D:** Anti-V5 and/or anti-EGFP immunostainings, with (left column) or without (right column) membrane permeabilization, and observed by confocal microscopy reveal PGRP-LBt can adopt both orientations in *Drosophila* membranes. GFP signal was used as a transfection control. Immunostainings performed with (left column) or without (right column) cell permeabilisation all exhibited signal associated with antibodies that were used, *i.e.* magenta signal for anti-EGFP staining, red signal for anti-V5 staining, or both. The latter was only observed in 70% of the cells: the remaining 30% only exhibited anti-V5 signal. Blue: DAPI; green: EGFP; magenta: anti-EGFP staining; red: anti-V5 staining.




**Figure S4: *pgrp-lb* inhibition effect on symbiont control and localization. Related to Figure 7.** **A:** Global symbiont density in larvae eight days following *pgrp-lb* or *pgrp-lbt* RNAi treatment. Symbiont density was calculated as the ratio between the numbers of *NuoCD* genomic copies (*S. pierantonius* gene) and of  $\beta$ -actin genomic copies (*S. zeamais* gene). A.U.: Arbitrary Units. The mean and standard error for eight independent replicates are represented. No significant difference was found based on a Student t-test. **B:** *S. pierantonius* localization by FISH eight days after *pgrp-lb* or *pgrp-lbt* RNAi treatment. No morphological differences were observed and no endosymbiont outside of the bacteriome was seen. Blue: DAPI; green: autofluorescence; red: *S. pierantonius*. **C:** Bactericidal assay of recombinant PGRP-LBi. *E. coli* were incubated for 18 h with increasing concentrations of recombinant PGRP-LBi, with and without ZnSO<sub>4</sub> (a necessary compound for amidase activity). The presence of PGRP-LBi had no effect on bacterial growth. **D-E:** *colA* expression in the bacteriome eight days after *pgrp-lb* (D) or *pgrp-lbt* (E) RNAi treatment. *colA* expression was measured in dissected bacteriomes by qRT-PCR eight days after *pgrp-lb* or *pgrp-lbt* extinction. A.U.: Arbitrary Units. The mean and standard error for five independent replicates are represented. No significant difference (n.s.) was found between two conditions based on a Welch's t-test.



**Figure S5: Development and validation of a novel TCT localization tool. Related to Figure 7.** **A:** Schematic representation of the construction and protocol. *Drosophila* PGRP-LE recognition domain is used as a TCT detector, linked to a V5 tag. An anti-V5 immunostaining is then performed to reveal TCT presence. **B:** Protein sequence of the PGRP-LE-V5 construction. Blue: 6His-tag for protein purification. Red: V5-Tag. Green: *Drosophila* PGRP-LE recognition domain. **C:** TCT localization in TCT-injected symbiotic larvae. Larvae were recovered 1 h after the injection in the fat body of 55 nL of a 0.2 mM solution of purified TCT. Two dilutions of PGRP-LE-V5 were tested, as well as a negative control without PGRP-LE (lower panels). Red signal is observed throughout the fat body and is proportional to PGRP-LE-V5 concentration, confirming the efficiency of the method. **D:** TCT localization in naive aposymbiotic larvae, which do not possess any natural source of TCT. Two dilutions of PGRP-LE-V5 were tested in order to evaluate the background signal due to aspecific staining, as well as a negative control without PGRP-LE (lower panels). Faint signal is observed at the higher PGRP-LE-V5 concentration (upper panels), while no signal is observed at the lower dilution (middle panel). The second dilution (650 ng/mL) was thus chosen for any further experiment, since it allows TCT recognition in positive controls (Figure S5C). mt: Malpighian tubules; bact: bacteriome; fb: fat body. Blue: DAPI; green: autofluorescence; red: TCT.



**Figure S6: Armadillo (upper panels) and Cut (middle panels) localization in larval tissues by immunostainings. Related to Figure 7.** A PBS negative control was included (lower panels). Both proteins are known to be strongly produced in the Malpighian tubules, supporting that the structures in which TCT was previously observed are indeed Malpighian tubules. Blue: DAPI; green: autofluorescence; red: Armadillo (upper panels) or Cut (middle panels).



**Figure S7: Efficiency of RNAi treatments. Related to the Material and Methods.** **A:** Transcript quantification after its inhibition by RNAi was measured in bacteriomes, carcasses, or aposymbiotic larvae by qRT-PCR six (*imd*, *relish*, *pgrp-lc*, *pgrp-lb* and *pgrp-lbt* in adults) or eight days (*pgrp-lb* and *pgrp-lbt* in larvae) following dsRNA injection. Specificity of the *pgrp-lbt* inhibition was also checked by quantifying *pgrp-lbe* and *pgrp-lbi* transcript levels. A.U.: Arbitrary Units. The mean and standard error for five independent replicates are represented. Asterisks indicate a significant difference between two conditions based on a Welch's t-test (\* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001). **B:** PGRP-LB localization in larval tissues by immunostaining eight days after *pgrp-lb* RNAi treatment. A pre-immune serum was used as the negative control (lower panels). PGRP-LB-associated signal is observed strongly in the bacteriome of RNAi *gfp* individuals (right upper panel), and is lost in RNAi *pgrp-lb* individuals (left upper panel). This confirms the efficiency of the RNAi at the protein level, as well as the specificity of the serum. Blue: DAPI; green: PGRP-LB; red: autofluorescence. Bact: bacteriome. **C:** DNA construction for *pgrp-lbt*-specific dsRNA synthesis. The upper panel is a schematic representation for the construction. The lower panel is the sequence of the DNA construction. TM-domain represents the transcript portion encoding the transmembrane domain, only specific sequence of the *pgrp-lbt* transcript. TM-domain was duplicated based on two different fragments, while preserving specific extremities for PCR amplification (in green and red).

**Table S1: Quantification of sugar and amino acid components in *S. pierantonius* PG after hydrolysis. Related to Figure 1.** Components in red are typically found in DAP-type PG.

	Replicate 1 (nmol)	Replicate 2 (nmol)
Asp	0.71	0.28
Thr	0.26	0.09
Ser	0.78	0.27
<b>Mur</b>	<b>0.2</b>	<b>0.12</b>
Glu	1.18	0.54
Gly	1.21	0.39
Ala	0.85	0.44
Val	0.22	0.09
<b>DAP</b>	<b>0.26</b>	<b>0.14</b>
Ile	0.17	0.06
Leu	0.45	0.14
Tyr	0.11	0.01
Phe	0.18	0.05
<b>GlcN</b>	<b>0.4</b>	<b>0.17</b>
Lys	0.26	0.08
His	0.1	0.08
Arg	0.28	0.02

**Table S2: Numbers of TCT-positive individuals, either the Malpighian tubules or the gut, after *pgrp-lb* or *pgrp-lbt* inhibition. Related to Figure 7.** n corresponds to the total of individuals that were observed for each condition.

	RNAi <i>gfp</i> (n = 7)	RNAi <i>pgrp-lb</i> (n = 15)	RNAi <i>pgrp-lbt</i> (n = 6)
Malpighian tubules	0	7	2
Gut	0	3	0

**Table S3: List of primers used for PCR, qPCR, dsRNA synthesis and plasmid constructions.**

	<b>Primers</b>	<b>Sequence (5'-3')</b>
PCR	5-pgrp-lbi/t-pcr	TCCAGTAAGCAATCACGGTCG
	3-pgrp-lbi/t-pcr	CTGTTTATACTCCTCGACGT
	5-pgrp-lbe-pcr	GTGTCTTGATTGGTAATATTC
	3-pgrp-lbe-pcr	TTACTGTTTATACTCCTCGACGT
qPCR	5-relish	CGTGGGCTTGAACAAAAAGGA
	3-relish	GGTGTGCCATGACCATCCA
	5-pgrp-lc	AGCATCACCACCCAACATTC
	3-pgrp-lc	TCACGGGTCCCATATATCCC
	5-imd	ATCCGGTAACCGAAGACGATA
	3-imd	ACAGTGGCTTTTAGTACCATTG
	5-coleoptericinA	GAATAGATAACAACGGGGTCA
	3-coleoptericinA	CTACCATCTGACACTTCCTC
	5-coleoptericinB	CTGATGTTGCCACTATCGC
	3-coleoptericinB	CCATGCTGGTTCACTTCCAC
	5-sarcotoxin	AGTCACAAAGGAACAATTTGG
	3-sarcotoxin	AGAACCGTCACGTCCGTT
	5-mdh	CCAAGAACAAACAAACACCG
	3-mdh	CTACACCAGGGAAAGATGTAT
	5-rpl29	TGGCCAAGTCCAAGAACATACA
	3-rpl29	TTCTGGCGCTAGCTTGTCTT
	5-gapdh	AACTTGCCGACAGCCTTGG
	3-gapdh	GCGCCCATGTATGTAGTTGG
	5-NuoCD	AATCGACGATCTCTCACCG
	3-NuoCD	GAATTGATCCCTTCGTCT
	5-β-tubulin	CAACTCCATCATGAAGTGC
	3-β-tubulin	CACATCTGTTGAAAGGTGGA
	5-pgrp-lbi	AGAGAAAAGAGTTGAATTAAATATAGTTGCGAAC
	3-pgrp-lbi	ATTGCATGTCATTATACATTCTC
	5-pgrp-lbt	TTACCCCAGGTTGCTCCAC
	3-pgrp-lbt	ATTGCATGTCATTATACATTCTC
	5-pgrp-lbe	GTGTCTTGATTGGTAATATTC
	3-pgrp-lbe	ATTGCATGTCATTATACATTCTC
RNAi	5-relish-T7	TAATACGACTCACTATAGGGCCAACATGGCGGATCCCATA
	3-relish-T7	TAATACGACTCACTATAGGGCGGGTGACCGCTTAAACCATC
	5-pgrp-lc-T7	TAATACGACTCACTATAGGGAGCGCCATACATCGAAAACG
	3-pgrp-lc-T7	TAATACGACTCACTATAGGGTCACCGCCACTATACTTCTCAC
	5-imd-T7	TAATACGACTCACTATAGGGACACAGGAACAGTTTCGTTCG
	3-imd-T7	TAATACGACTCACTATAGGGCGAATCCAATCCAGCAAGAACTG

	5-pgrp-lb-T7	TAATACGACTCACTATAGGGCCAGTCCCTACGTCGTCA
	3-pgrp-lb-T7	TAATACGACTCACTATAGGGTCTGTTCTCGGACTTGCCT
	5-pgrp-lbt-T7	TAATACGACTCACTATAGGGCCCCAGGTTGCTCCACAT
	3-pgrp-lbt-T7	TAATACGACTCACTATAGGGAAATGTTGCACATATGATGACT
	5-gfp-T7	TAATACGACTCACTATAGGGCAAGGAGGACGGCAACATCC
	3-gfp-T7	TAATACGACTCACTATAGGGATTTATGTTCAGGTTCAG
DNA constructs	5_TM-domain_F1	CCCCAGGTTGCTCCACAT
	3_TM-domain_F1_ClaI	ATCGATGCGATGACTAACACTGCAC
	5_TM-domain_F2_ClaI	CCGATCGATTACCCCCAGAATTCTGGAG
	3_TM-domain_F2_ClaI	CCCATCGATAATGTTGCACATATGATGACT
	pgrp-lbi-S2-EcoRI-for	CCGGAATTCATGTCCAGTAAGCAATCACGGTCGA
	pgrp-lbi-S2-EcoRV-rev	CCGGATATCCCTGTTTATACTCCTCGACGTAC
	pgrp-lbt-S2-EcoRV-for	CCGGATATCATGTCCAGTAAGCAATCACGGTCG
	pgrp-lbt-S2-Xhol-rev	CCGCTCGAGCTGTTTATACTCCTCGACGTACT
	Fw_EGFP_KpnI	CGGGGACCTACTCCAGTATGGTGAGCAAGGGCGAGGA
	Rv_EGFP_EcoV	CCGGAATGAATTCTTGTACAGCTCGTCCATGC

**Supplementary sequences: Sequences of the putative PGRP-LB proteins and transcripts identified in this study from three weevil species (*Sitophilus zeamais*, *Sitophilus oryzae* and *Sitophilus linearis*), from RNAseq data. Related to Figure 3.** Protein sequences of the different isoforms were aligned for each species, in which the residues essential to enzymatic activity are shown in green, the transmembrane domain in red, the peptide signal in purple and the N-terminal region, specific to PGRP-LBi and -LBt without particular feature in grey. The specific PGRP-LBi and -LBt N-terminal sequences (grey and red) do not show homology with any sequence of the NCBI database.

### ***Sitophilus zeamais* PGRP-LB protein sequences**

Szeamais_PGRP-LBi	MSSKQSR SIVPTCECKFEKME EIGEK KVELNIV-----	33
Szeamais_PGRP-LBT	MSSKQSR SIVPTCECKFEKME EIGEK KVELNIVPQVAPHYPQNSWRSLLTKSRLILIVTV	60
Szeamais_PGRP-LBe	-----MCYNSC	6
Szeamais_PGRP-LBi	-----ANSFVCTDPEIVTRDEWGAKPPTGVENLTLPPVYVVIHSYIPAACSTK	82
Szeamais_PGRP-LBT	LVI AVI ICATFANSFVCTDPEIVTRDEWGAKPPTGVENLTLPPVYVVIHSYIPAACSTK	120
Szeamais_PGRP-LBe	VLIWVIFTCHVANSFVCTDPEIVTRDEWGAKPPTGVENLTLPPVYVVIHSYIPAACSTK*****	66
Szeamais_PGRP-LBi	EECINDMQWMQNYHQQNNSWCDIGYNFAVGGDNRIYVGRGWTAVGAHAPRYNARSIGIVL	142
Szeamais_PGRP-LBT	EECINDMQWMQNYHQQNNSWCDIGYNFAVGGDNRIYVGRGWTAVGAHAPRYNARSIGIVL	180
Szeamais_PGRP-LBe	EECINDMQWMQNYHQQNNSWCDIGYNFAVGGDNRIYVGRGWTAVGAHAPRYNARSIGIVL*****	126
Szeamais_PGRP-LBi	IGDWTEILPPESQMLAAKQLINMGIRDGYISENYKLIGRQVRETECPGEALYKEIQTWP	202
Szeamais_PGRP-LBT	IGDWTEILPPESQMLAAKQLINMGIRDGYISENYKLIGRQVRETECPGEALYKEIQTWP	240
Szeamais_PGRP-LBe	IGDWTEILPPESQMLAAKQLINMGIRDGYISENYKLIGRQVRETECPGEALYKEIQTWP*****	186
Szeamais_PGRP-LBi	HWDNPSDLDEVIPVVPLDKEDLKPDPRDSGASLASEDNKIKRHSSTHKEESTSRSIKQ	262
Szeamais_PGRP-LBT	HWDNPSDLDEVIPVVPLDKEDLKPDPRDSGASLASEDNKIKRHSSTHKEESTSRSIKQ	300
Szeamais_PGRP-LBe	HWDNPSDLDEVIPVVPLDKEDLKPDPRDSGASLASEDNKIKRHSSTHKEESTSRSIKQ*****	246

#### **>Szeamais\_PGRP-LBi TRINITY\_DN43557\_c0\_g1\_i2**

MSSKQSR SIVPTCECKFEKME EIGEK KVELNIVANSFVCTDPEIVTRDEW  
GAKPPTGVENLTLPPVYVVIHSYIPAACSTKEECINDMQWMQNYHQQN  
SWCDIGYNFAVGGDNRIYVGRGWTAVGAHAPRYNARSIGIVLIGDWTEIL  
PPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETECPGEALYKEIQT  
WPHWIDNPSDLDEVIPVVPLDKEDLKPDPRDSGASLASEDNKIKRHSST  
HKEESTSRSIKQ

#### **>Szeamais\_PGRP-LBt TRINITY\_DN43557\_c0\_g1\_i5**

MSSKQSR SIVPTCECKFEKME EIGEK KVELNIVPQVAPHYPQNSWRSLLT  
KSRII LIVTVLVI AVI ICATFANSFVCTDPEIVTRDEWGAKPPTGVENLT  
LPVYVVIHSYIPAACSTKEECINDMQWMQNYHQQNNSWCDIGYNFAVG  
GDNRIYVGRGWTAVGAHAPRYNARSIGIVLIGDWTEILPPESQMLAAKQL

INMGIRDGYISENYKLIGHRQVRETECPGEALYKEIQTWPHIDNPSLDD  
EVIPVPLDKEDLKPDPREDSGASLASEDNKIKRHSSTHKEESTSRSIKQ

**>Szeamais\_PGRP-LBe TRINITY\_DN43557\_c0\_g1\_i3**

MCYNSCVLIWVIFTCHVANSFVCTDPEIVTRDEWGAKPPTGVENLTLPPV  
YVVIHHSYIPAACSTKEECINDMQWMQNYHQQNNSWCDIGYNFAVGGDNR  
IYVGRGWTAVGAHAPRYNARSIGIVLIGDWTEILPPESQMLAAKQLINMG  
IRDGYISENYKLIGHRQVRETECPGEALYKEIQTWPHIDNPSLDEVIP  
VVPLDKEDLKPDPREDSGASLASEDNKIKRHSSTHKEESTSRSIKQ

***Sitophilus oryzae* PGRP-LB protein sequences**

Soryzae_PGRP-LBi	MSSKQSRSPVTRECQFEKMEEIEEQKVKLNI-----	31
Soryzae_PGRP-LBt	MSSKQSRSPVTRECQFEKMEEIEEQKVKLNIASQVASHYPQNSWRSLLT KSRIILIVTVL	60
Soryzae_PGRP-LBe1	-----MCYNICV	7
Soryzae_PGRP-LBe2	-----MICY	4
Soryzae_PGRP-LBe3	-----MISY	4
Soryzae_PGRP-LBi	-----VANSFVCTDPEIVTRDEWGAKPPTDVENLTLPPVYVVIHSYIPAACSTKE VIAVIICGTFANSEVCTDPEIVTRDEWGAKPPTDVENLTLPPVYVVIHSYIPAACSTKE	82
Soryzae_PGRP-LBt	LIWVILTCVANSFVCTDPEIVTRDEWGAKPPTDVENLTLPPVYVVIHSYIPAACSTKE	120
Soryzae_PGRP-LBe1	SLVSLYLFRVANSFVCTDPEIVTRDEWGAKPPTDVENLTLPPVYVVIHSYIPAACSTKE	67
Soryzae_PGRP-LBe2	ILVILCYFTVANSFVCTDPEIVTRDEWGAKPPTDVENLTLPPVYVVIHSYIPAACSTKE	64
Soryzae_PGRP-LBe3	*****	64
Soryzae_PGRP-LBi	ECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLI	142
Soryzae_PGRP-LBt	ECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLI	180
Soryzae_PGRP-LBe1	ECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLI	127
Soryzae_PGRP-LBe2	ECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLI	124
Soryzae_PGRP-LBe3	ECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLI	124
Soryzae_PGRP-LBi	GDWTDILPPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH	202
Soryzae_PGRP-LBt	GDWTDILPPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH	240
Soryzae_PGRP-LBe1	GDWTDILPPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH	187
Soryzae_PGRP-LBe2	GDWTDILPPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH	184
Soryzae_PGRP-LBe3	GDWTDILPPESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH	184
Soryzae_PGRP-LBi	WIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRSIKHT	260
Soryzae_PGRP-LBt	WIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRSIKHT	298
Soryzae_PGRP-LBe1	WIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRSIKHT	245
Soryzae_PGRP-LBe2	WIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRSIKHT	242
Soryzae_PGRP-LBe3	WIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRSIKHT	242

**>Soryzae\_PGRP-LBi TRINITY\_DN16375\_c4\_g1\_i2**

MSSKQSRSPVTRECQFEKMEEIEEQKVKLNI VANSFVCTDPEIVTRDEWG  
AKPPTDVENLTLPPVYVVIHSYIPAACSTKEECINDMQWMQKYHQQNNS  
WCDIGYNFAVGGDNRIFYVGRGWTAVGAHAPRYNRSIGIVLIGDWTDILP  
PESQMLAAKQLINMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWH  
PHWIPNPDEEVIPVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKD  
ESTSRSIKHT

**>Soryzae\_PGRP-LBt TRINITY\_DN16375\_c4\_g1\_i4**

MSSKQSRSPVTRECQFEKMEEIEEQKVKLNIASQVASHYPQNSWRSLLT

SRIILIVTVLVIAVIICGTFANSFVCTDPEIVTRDEWGAKPPTDVENLTL  
 PVPYVVIHHSYIPAACSTKEECINDMQWMQKYHQQNNSWCDIGYNFAVGG  
 DNRIYVGRGWTAVGAHAPRYNSRSIGIVLIGDWTDLPPESQMLAAKQLI  
 NMGIRDGYISENYKLIGHRQVRETACPGEALYKEIQMWPHIPNPDEEVIP  
 PVVPLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRISKHT

**>Soryzae\_PGRP-LBe1 TRINITY\_DN16375\_c4\_g1\_i1**

MCYNICVLIWVILTCHVANSFVCTDPEIVTRDEWGAKPPTDVENLTL  
 PVPYVVIHHSYIPAACSTKEECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNR  
 IYVGRGWTAVGAHAPRYNSRSIGIVLIGDWTDLPPESQMLAAKQLINMG  
 IRDGYISENYKLIGHRQVRETACPGEALYKEIQMWPHIPNPDEEVIPVV  
 PLDKEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRISKHT

**>Soryzae\_PGRP-LBe2 TRINITY\_DN16375\_c4\_g1\_i3**

MICYSLVSLYLFRVANSFVCTDPEIVTRDEWGAKPPTDVENLTL  
 PVPYVVIHHSYIPAACSTKEECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNR  
 IYVGRGWTAVGAHAPRYNSRSIGIVLIGDWTDLPPESQMLAAKQLINMGIRD  
 GYISENYKLIGHRQVRETACPGEALYKEIQMWPHIPNPDEEVIPVVPLD  
 KEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRISKHT

**>Soryzae\_PGRP-LBe3 TRINITY\_DN16375\_c4\_g1\_i5**

MISYILVILCYFTVANSFVCTDPEIVTRDEWGAKPPTDVENLTL  
 PVPYVVIHHSYIPAACSTKEECINDMQWMQKYHQQNNSWCDIGYNFAVGGDNR  
 IYVGRGWTAVGAHAPRYNSRSIGIVLIGDWTDLPPESQMLAAKQLINMGIRD  
 GYISENYKLIGHRQVRETACPGEALYKEIQMWPHIPNPDEEVIPVVPLD  
 KEDLKPDPREDPDASLASEDNEIKRHSSTDKDESTSRISKHT

### *Sitophilus linearis* PGRP-LB protein sequences

Slinearis_PGRP-LBe1	MCLCVTLCAVISVILICDVVNSFVYPDPEIVTREEWCAKPPTSVEKLTL Slinearis_PGRP-LBe2	-----MINYIFAVLCYFN : : :: *: : ****	60
			55
Slinearis_PGRP-LBe1	IPIAACYNKECINAMQWMQKFHQQNRSWCDIGY Slinearis_PGRP-LBe2	YNA : *****	120
			115
Slinearis_PGRP-LBe1	TKSMGIVLIGNWEDILPPESQMLVA Slinearis_PGRP-LBe2	KQLINMGIRGGYISKNYKLIGHRQVRE : *****	180
			175
Slinearis_PGRP-LBe1	YEEIQTWPHTENPTLEIRRDPV Slinearis_PGRP-LBe2	VLSKEHV : *****	239
			234

**>Slinearis\_PGRP-LBe1 TRINITY\_DN65546\_c3\_g3\_i7**

MCLCVTLCAVISVILICDVVNSFVYPDPEIVTREEWCAKPPTSVEKLTL  
 VPYVVIHHSYIPAACYNKECINAMQWMQKFHQQNRSWCDIGYNFAVGGD  
 NR  
 IYVGRGWTAVGAHAPLYNTKSMGIVLIGNWEDILPPESQMLVA  
 MGIRGGYISKNYKLIGHRQVRE  
 T  
 VCPGQAL  
 YEEIQTWPHTENPTLEIRRDPV  
 LSKEHV  
 KPDREEFDARLSFENNQVR  
 RSSINKE

**>Slinearis\_PGRP-LBe2 TRINITY\_DN65546\_c3\_g3\_i5**

MINYIFAVLCYFNVVNSFVYPDPEIVTREEWCAKPPTSVEKTLPLPVYVV  
IHHSYIPAACYNKECINAMQWMQKFHQQNRSWCDIGYNFAVGGDNRIYV  
GRGWTAVGAHAPLYNTKSMGIVLIGNWEDILPPESQMLVAKQLINMGIRG  
GYISKNYKLIGHRQVRETVC PGQALYEEIQTWPHFTENPTLEIRRDVPVS  
LDKEHVVKPDPREEFDARLSFENNQVRSSINKE

---

**Sitophilus zeamais PGRP-LB transcript sequences**

---

**>Szeamais\_PGRP-LBi TRINITY\_DN43557\_c0\_g1\_i2 len=1098**

TGTCCCAGCAACAACAAGTCTGTAATGTCCAGTAAGCAATCACGGTCGATAGTACCCACG  
TGCAGTGTAAGTCAAAAATGGAAGAAATTGGAGAGAAAAAGTTGAATTAAATATA  
GTTGCGAACAGCTCGTATGTACAGACCCGGAAATAGTTACGAGGGACGAATGGGTGCC  
AAACCACCCACGGCGTGGAAAACTTAACTCTACCAGTCCCTACGTCGTACACACCAC  
AGTTATATACCTGCAGCTGTTCAACAAAAGAGGAATGTATAATGACATGCAATGGATG  
CAAAACTATCATCAACAAAATAATTCATGGTGCATATTGGATATAATTCGCTGTTGGA  
GGGGACAACAGAACATTACGTTGGACGAGGTTGGACAGCTGTAGGAGCCCACGCTCCCCGT  
TACAATGCCAGAACATGGAATCGTCCTGATAGGAGATTGGACAGAAATATTACCTCCA  
GAGAGTCAAATGTTAGCAGCAAAACAATTGATTAATATGGAATCAGAGACGGCTATATA  
AGTAAAACATCAAATTAAATTGGTCATAGGCAAGTCCGAGAAACAGAAATGTCCAGGAGAA  
GCATTATATAAAGAGATCCAAACGTGGCCTCACTGGATAGACAACCCCAGCCTCGACGAC  
GAGGTCTTCCTGTAGTACCTCTAGACAAAGAAGACCTAAACAGATCCCAGAGAGGAT  
TCTGGTGCTAGCTGGCATCTGAAGATAATAAAATTAAACGACATAGTTCTACACACAAA  
GAGGAAAGTACGTCGAGGAGTATAAAACAGTAATACATAAAACTATCTTCACTCTAAT  
TGTGTTAAAAATGATGTTCTTATTAAGCTAATATAGACAATTAAACTTCTTCAATC  
AAACATTGAGGTTCACTGGACGAGAAATTCCAACGTGTTGTGCAAATATGCTCTGAA  
AAAACCTAGAGATAGATTCGTTATATGTATATGAAACCATCAAATAAGTGATTAACGA  
TGTTTATACAACGTTCTATTTAAAGTATTTTTAAATATCTTGTAACTATTACAG  
TCTTCATTAATAAAAGTT

**>Szeamais\_PGRP-LBt TRINITY\_DN43557\_c0\_g1\_i5 len=1212**

TGTCCCAGCAACAACAAGTCTGTAATGTCCAGTAAGCAATCACGGTCGATAGTACCCACG  
TGCAGTGTAAGTCAAAAATGGAAGAAATTGGAGAGAAAAAGTTGAATTAAATATA  
GTACCCAGGTTGCTCACATTACCCCCAGAATTCTGGAGGAGTTATTAACAAAATCA  
AGAATAATTCTAATTGTGACAGTGTAGTCATCGCAGTCATCATATGTGCAACATTTGGC  
AACAGCTCGTATGTACAGACCCGGAAATAGTTACGAGGGACGAATGGGTGCCAAACCA  
CCCACGGCGTGGAAAACTTAACTCTACCAGTCCCTACGTCGTACACACCACAGTTAT  
ATACCTGCAGCTGTTCAACAAAAGAGGAATGTATAATGACATGCAATGGATGCAAAC  
TATCATCAACAAAATAATTCATGGTGCATATTGGATATAATTCGCTGTTGGAGGGAC  
AACAGAATTACGTTGGACGAGGTTGGACAGCTGTAGGAGCCCACGCTCCCCGTTACAAT  
GCCAGAAGCATTGGAAATCGTCCTGATAGGAGATTGGACAGAAATATTACCTCCAGAGAGT  
CAAATGTTAGCAGCAAAACAATTGATTAATATGGAATCAGAGACGGCTATATAAGTGA  
AACTACAAATTAAATTGGTCATAGGCAAGTCCGAGAAACAGAAATGTCCAGGAGAACGATTA  
TATAAAGAGATCCAAACGTGGCCTCACTGGATAGACAACCCCAGCCTCGACGACGAGGTC  
ATTCTGTAGTACCTCTAGACAAAGAAGACCTAAACAGATCCCAGAGAGAGGATTCTGGT  
GCTAGCTTGGCATCTGAAGATAATAAAATTAAACGACATAGTTCTACACACAAAGAGGAA

AGTACGTCGAGGAGTATAAAACAGTAATACATAAAAActATCTTCACTCTAATTGTGTT  
AAAAAATGATGTTCTTATTAAGCTAATATAGACAATTAAAActTCTTCAATCAAACAT  
TGAGGTTCACTGGACGAGAAAATTCCAACGTGTTGTGCAAATATGCTCTGAAAAAACC  
TAGAGATAGATTCGTTATATGTATATGAAACCATCAAATAAAGTGATTAACGATGTTA  
TACAACGTTCTATTTAAAGTATTTTTAAATATCTTGTAACTATTACAGTCTTC  
ATTAATAAAGTT

**>Szeamais\_PGRP-LBe TRINITY\_DN43557\_c0\_g1\_i3 len=1272**

TTCCAGCATACCCCGCGCAGATATGCTATATAATATAATAGTCAAGGACCAAGCATT CGG  
AGGCAAAAATTGAAAGTATTAACAGCATT CATATCAAATGTAGACAGAACAGGGA  
ATTTAAAGATATTTAAGGATGTAAAATTGTTAAAATTAGTTCTTCTACAAAAGC  
CTGTGAAACTAActGAAAGTGTATCTGTGATATTAGTGGAGTTAGTTACTATTATT  
TTAAGATGTGTTATAATAGTTGTCTTGATTTGGTAATATTACATGTCATGTTGCG  
AACAGCTCGTATGTACAGACCCGGAAATAGTTACGAGGGACGAATGGGGGCCAAACCA  
CCCACGGCGTGGAAAActTAActCTACCAGTCCCTACGTCGTACACACCACAGTTAT  
ATACCTGCAGCTTGTCAACAAAAGAGGAATGTATAATGACATGCAATGGATGCAAAC  
TATCATCAACAAAATAATTCACTGGTGCATATTGGATATAATTCGCTGTTGGAGGGAC  
AACAGAATTACGTTGGACGAGGTTGGACAGCTGTAGGAGCCCACGCTCCCCGTTACAAT  
GCCAGAACATTGGAATCGTCCTGATAGGAGATTGGACAGAAATATTACCTCCAGAGAGT  
CAAATGTTAGCAGCAAAACAATTGATTAATATGGAATCAGAGACGGCTATATAAGTGA  
AACTACAAATTAAATTGGTCATAGGCAAGTCCGAGAAACAGAAATGTCAGGAGAACATTA  
TATAAAGAGATCCAAACGTGGCCTCACTGGATAGACAACCCAGCCTCGACGACGAGGTC  
ATTCCGTAGTACCTCTAGACAAAGAACCTTAAACCAGATCCCAGAGAGGATTCTGGT  
GCTAGCTGGCATCTGAAGATAATAAATTAAACGACATAGTTCTACACACAAAGAGGAA  
AGTACGTCGAGGAGTATAAAACAGTAATACATAAAAActATCTTCACTCTAATTGTGTT  
AAAAAATGATGTTCTTATTAAGCTAATATAGACAATTAAAActTCTTCAATCAAACAT  
TGAGGTTCACTGGACGAGAAAATTCCAACGTGTTGTGCAAATATGCTCTGAAAAAACC  
TAGAGATAGATTCGTTATATGTATATGAAACCATCAAATAAAGTGATTAACGATGTTA  
TACAACGTTCTATTTAAAGTATTTTTAAATATCTTGTAACTATTACAGTCTTC  
ATTAATAAAGTT

---

**Sitophilus oryzae PGRP-LB transcript sequences**

---

**>Soryzae\_PGRP-LBi TRINITY\_DN16375\_c4\_g1\_i2 len=1263**

CGCATCCCTAAGAACATAGGACATTGTTAGACAGTCAGCGAAAAGTATCATTAGTCT  
TATAAGTACCACAATTATTTATCTGTTATTGATAACAGTCGATAAACTTAGACCGAT  
TTAAATATTTAGGGATTACTAACCTTCGGGCTTCAGTGTAGTGTAAATAAGTCTGTAAA  
AAAGGTATGTCCAGTAAGCAGTCACGGTCGGTACCCACGCCGAGTGTCAAGTTGAAAAA  
ATGGAAGAAATTGAAGAGCAAAAGTCAAACAAATATAGTTGCGAACAGCTCGTATGT  
ACAGACCCGGAAATAGTTACGAGGGACGAATGGGGGCCAAACCACCCACAGATGTTGAA  
AACTTAACCTACAGTTCTACGTCGTACACACCAGTTATACCTGCAGCTTGT  
TCAACAAAAGAGGAATGTATAATGACATGCAATGGATGCAAAAGTATCATCAACAAAAT  
AATTCACTGGTGCATATTGGATATAATTCGCTGTTGGAGGGACAATAGAATTACGTT  
GGACGAGGTTGGACAGCTGTAGGGGCCACGCTCCCCGTACAATTCCAGAAGCATTGGA  
ATAGTCCTGATAGGAGATTGGACAGATATATTACCCCCAGAGAGTCAAATGTTAGCAGCA  
AAACAACGTATAATATGGAAATCAGAGACGGCTATATAAGTAAAACACTACAAATTAAATT  
GGGCATAGGCAAGTCCGAGAGACAGCATGTCCAGGAGAAGCATTATATAAGGAGATCCAA  
ATGTGGCCTCACTGGATCCCCAACCCCGATGAAGAGGTATTCTGTAGTACCTCTAGAC  
AAAGAACCTTAAACCAGATCCCAGAGAAGATCCGGATGCCAGCTGGCATCTGAAGAT  
AATGAAATTAAACGACATAGTTCTACAGACAAGGATGAAAGTACGTCGAGGAGTATAAAA  
CATACATAAAAACATCTTCCACTCTAATTGTGTTAAAATTATGTTCTTATTAAGCT  
AATAGATCATTTAAACTTTTTTATCAAACATTGAGGTTACTGGACGAGAAAATTCCA  
ACGTGTTGTGCAAATATGCTCTAAAAACCTACAGATAGATTGTTACTCGTA  
TGTATCTGAATCCATCAAATAAAGTGATTAACGATATTATACGACGTTCTATTAAA  
GTATTTTAAATCTCTTGTAACTATTACTGTTCTTAATAAGTTCATATCAAAA  
AAA

**>Soryzae\_PGRP-LBt TRINITY\_DN16375\_c4\_g1\_i4 len=1377**

CGCATCCCTAAGAACATAGGACATTGTTAGACAGTCAGCGAAAAGTATCATTAGTCT  
TATAAGTACCACAATTATTTATCTGTTATTGATAACAGTCGATAAACTTAGACCGAT  
TTAAATATTTAGGGATTACTAACCTTCGGGCTTCAGTGTAGTGTAAATAAGTCTGTAAA  
AAAGGTATGTCCAGTAAGCAGTCACGGTCGGTACCCACGCCGAGTGTCAAGTTGAAAAA  
ATGGAAGAAATTGAAGAGCAAAAGTCAAACAAATATGACATCACAGGTTGCTTCACAT  
TACCCCCAGAATTCTGGAGGAGCTTATTAACAAAATCAAGAATAATTCTAATTGTGACA  
GTGTTAGTCATCGCAGTCATCATATGTGGCACATTGCGAACAGCTCGTATGTACAGAC  
CCGGAAATAGTTACGAGGGACGAATGGGGGCCAAACCACCCACAGATGTTGAAAATTAA  
ACTCTACCACTGTTCTACGTCGTACACACCAGTTATACCTGCAGCTGTTCAACA  
AAAGAGGAATGTATAATGACATGCAATGGATGCAAAAGTATCATCAACAAAATAATTCA  
TGGTGCATATTGGATATAATTCGCTGTTGGAGGGACAATAGAATTACGTTGGACGA  
GGTTGGACAGCTGTAGGGGCCACGCTCCCCGTACAATTCCAGAAGCATTGGAATAGTC  
CTGATAGGAGATTGGACAGATATATTACCCCCAGAGAGTCAAATGTTAGCAGCAAAACAA  
CTGATTAATATGGAAATCAGAGACGGCTATATAAGTAAAACACTACAAATTGTTGGCAT  
AGGCAAGTCCGAGAGACAGCATGTCCAGGAGAAGCATTATATAAGGAGATCCAAATGTGG  
CCTCACTGGATCCCCAACCCCGATGAAGAGGTATTCTGTAGTACCTCTAGACAAAGAA  
GACCTTAAACCAGATCCCAGAGAAGATCCGGATGCCAGCTGGCATCTGAAGATAATGAA  
ATTAAACGACATAGTTCTACAGACAAGGATGAAAGTACGTCGAGGAGTATAAAACATACA  
TAAAAACTATCTTCCACTCTAATTGTGTTAAAATTATGTTCTTATTAAGCTAATAGA

TCATTAAAACTTTTTTATCAAACATTGAGGTTCACTGGACGAGAAAATTCCAACGTGT  
TGTGTGCAAATATGCTCTCAAAAAAACCTACAGATAGATTCGTTACTCGTATGTATC  
TGAATCCATCAAATAAAGTGATTAACGATATTACGACGTTCTATTAAAGTATT  
TTAAATCTCTTGTAACTATTACTGTCTTCATTAATAAAGTCATATCAAAAAAA

**>Soryzae\_PGRP-LB<sub>e1</sub> TRINITY\_DN16375\_c4\_g1\_i1 len=1249**

CA GT AT TA AC AG CATT CAT AT CAA AT GTAG A AAG A A A CAG ACT TAA CG CA AG CT AA AT  
TTGCCAATTCAATGAGTTCTAATTGAATT TAGTTAAAGAGATTAAAGATGTAAAAA  
ATTGTAAAAGTTAGTTCTACAAAAGCCTGTGAATCTAACCAAAAGTGTATACGT  
TGATATTAGTGTGGTTACTTAATATTGTAAAATGTGTATAATATTGTGTCTT  
GATTGGGTAAATTGACATGTATGTCGAACAGCTCGTATGTACAGACCCGGAAAT  
AGTTACGAGGGACGAATGGGTGCCAACCACCCACAGATGTTGAAACTTAACCTAC  
AGTCCTTACGTCGTACACACCACAGTTATACCTGCAGCTGTCAACAAAAGAGGA  
ATGTATAAATGACATGCAATGGATGAAAAGTATCATCACAAATAATTGTCGCA  
TATTGGATATAATTGCTGTTGGAGGGACAATAGAATTACGTTGGACGAGGTTGGAC  
AGCTGTAGGGGCCACGCTCCCCGTACAATTCCAGAACAGCTGGAATAGTCCTGATAGG  
AGATTGGACAGATATATTACCCCCAGAGAGTCAAATGTTAGCAGCAAAACAACGTATTAA  
TATGGGAATCAGAGACGGCTATATAAGTAAAAACTACAAATTAAATTGGCATAGGCAAGT  
CCGAGAGACAGCATGTCCAGGAGAACGATTATATAAGGAGATCCAATGTGGCTCACTG  
GATCCCCAACCCGATGAAGAGGTATTCTGTAGTACCTCTAGACAAAGAACCTTAA  
ACCAGATCCCAGAGAACGATCCGGATGCCAGCTGGCATCTGAAGATAATGAAATTAAACG  
ACATAGTTCTACAGACAAGGATGAAAGTACGTCGAGGAGTATAAACATACATAAAACT  
ATCTTCCACTCTAATTGTTAAAATTATGTTCTTATTAAAGCTAATAGATCATTAA  
ACTTTTTTATCAAACATTGAGGTTCACTGGACGAGAAAATTCCAACGTGTGTGCA  
AATATGCTCTCAAAAAACCTACAGATAGATTGTTACTCGTATGTATCTGAATCCA  
TCAAATAAAGTGATTAACGATATTACGACGTTCTATTAAAGTATTAAAC  
TCTTGTAACTATTACTGTCTTCATTAATAAAGTCATATCAAAAAAA

**>Soryzae\_PGRP-LB<sub>e2</sub> TRINITY\_DN16375\_c4\_g1\_i3 len=1104**

AATACAATCTGGCACAGTTTCGTTAGTCGTCAAAACAAAACAATTTCCTTATA  
AGTGTCAATTATTATTGTTAAATGATTGTTATAGTTAGTTCTTGTACTGTTCGA  
GTTGCGAACAGCTCGTATGTACAGACCCGGAAATAGTTACGAGGGACGAATGGGTGCC  
AAACCACCCACAGATGTTAAAACTTAACCTACAGCTTACGTCGTACACACCAC  
AGTTATATACCTGCAGCTGTTCAACAAAAGAGGAATGTATAATGACATGCAATGGATG  
CAAAAGTATCATCAACAAAATAATTGTCGATATTGGATATAATTGCTGTTGGA  
GGGGACAATAGAATTACGTTGGACGAGGTTGGACAGCTGTAGGGGCCACGCTCCCCGT  
TATAATTCCAGAACGATTGGAATCGTCTGATAGGAGATTGGACAGATATTACCCCCA  
GAGAGTCAAATGTTAGCAGACAAACTGATTAATATGGAATCAGAGACGGCTATATA  
AGTAAAACACTACAAATTAAATTGGGCATAGGCAAGTCCGAGAGACAGCATGTCCAGGAGAA  
GCATTATATAAGGAGATCAAATGTGGCTCACTGGATCCCCAACCCGATGAAGAGGTC  
ATTCTGTAGTACCTCTAGACAAAGAACCTTAAACCAGATCCCAGAGAACGATCCGGAT  
GCCAGCTGGCATCTGAAGATAATGAAATTAAACGACATAGTTCTACAGACAAGGATGAA  
AGTACGTCGAGGAGTATAAACATACATAAAACTATCTCCACTCTAATTGTTAA  
AATTATGTTCTTATTAAAGCTAATAGATCATTAAACTTTTTTATCAAACATTGAGGT  
TCACTGGACGAGAAAATTCCAACGTGTTGTGCAAATATGCTCTAAAAACCTACAG  
ATAGATTCGTTACTCGTATGTATCTGAATCCATCAAATAAAGTGATTAACGATATT  
ATACGACGTTCTATTAAAGTATTAAATCTCTTGTAACTATTACTGTCTTCA  
TTAATAAAGTCATATCAAAAAAA

**>Soryzae\_PGRP-LB<sub>e3</sub> TRINITY\_DN16375\_c4\_g1\_i5 len=1127**

CTTGCACAGTTTCGTTAACCGTGTCAAACAACAATCGTAGTCGAGAGTACCTACA  
CTAACTAATAGTTACAGTTATTTTACAAGAACATACCCATAAAATGATTAGTTATTT  
TAGTTATTCTATGTTATTTACTGTTGCGAACAGCTCGTATGTACAGACCCGGAAATAG  
TTACGAGGGACGAATGGGGTGCACAAACCACCCACAGATGTTGAAAACCTAACTCTACCAG  
TTCCTACGTGTCATACACCACAGTTATACCTGCAGCTGTTCAACAAAAGAGGAAT  
GTATAATGACATGCAATGGATGCAAAGTATCATCAACAAAATAATTGATGGTGCGATA  
TTGGATATAATTCGCTGTTGGAGGGACAATAGAATTACGTTGGACGAGGTTGGACAG  
CTGTAGGGGCCACGCTCCCCGTTACAATTCCAGAAGCATTGGAATAGTCCTGATAGGAG  
ATTGGACAGATATATTACCCCCAGAGAGTCAAATGTTAGCAGCAAACAAACTGATTAATA  
TGGGAATCAGAGACGGCTATATAAGTGAAAACACAAATTAGGCATAGGCAAGTCC  
GAGAGACAGCATGTCAGGAGAACATTATATAAGGAGATCCAAATGTTGGCCTCACTGGA  
TCCCCAACCCCGATGAAGAGGTATTCTGTAGTACCTCTAGACAAAGAACCTTAAAC  
CAGATCCCAGAGAACATCCGGATGCCAGCTGGCATCTGAAGATAATGAAATTAAACGAC  
ATAGTTCTACAGACAAGGATGAAAGTACGTCGAGGAGTATAAAACATACATAAAACTAT  
CTTCCACTCTAATTGTTAAAAATTATGTTCTATTAGCTAATAGATCATTAAAC  
TTTTTTTATCAAACATTGAGGTTCACTGGACGAGAAAATCCAACGTGTTGTGCAAA  
TATGCTCTCAAAAAACCTACAGATAGATTCTGTTACTCGTATGTATCTGAATCCATC  
AAATAAAAGTATTAACGATATTATACGACGTTCTATTAAAGTATTTAAATCTC  
TTGTAACATTACTGTTCTTACAAATAAGTACATCAAAAAAA

---

### **Sitophilus linearis PGRP-LB transcript sequences**

---

**>Slinearis\_PGRP-LB1 TRINITY\_DN65546\_c3\_g3\_i7 len=1265**  
CCCCAGCTAAAGTTGGCGGGCTACTTTGAACACCCGTATACATGTAGGCAGTACT  
ATGTAACAACTAACAGGTATCTATCTATGAGTAATTAGTAGTTACTTTCAACAGCTCTAG  
TGAGAACTGTCGACATTAGCGTCCACTAAATTAAATTATTGTCTGTGATTACCCGT  
TTGCCCCCCCCCTCCCTCCTTCAGCATAACCCCCGCGCTATATAATAACAGTCGAGG  
ATTCAAGGCTTAAATTCAAAGCATTACAGCATTGCTATCAATGGAACATGACTCGAA  
TCCAAACTAAATTCTATTGAAATATCTCCCTCACAAAGCTTGTGAAATTAAACTG  
ATATTTTTTAATATGTGTTATGTGTTACTCTTGTGCTGTCAATTGTAATACTG  
ATCTGTGATGTTGTGAACAGTTCGTATATCCCGACCTGAAATTGTTACGAGGGAGGAA  
TGGTGCACAAACGCCACATCCGTTGAGAAATTAACTCTACCCGCTTACGTTGTC  
ATACACCACAGTTATACCTGCAGCTTACAACAAGGAGGAATGTATAATGCAATG  
CAATGGATGCAAAGTTCATCAACAAATCGCTATGGTGCATATTGGATACAATTG  
GCTGTTGGAGGGATAACAGAATATACGTGGAAAGGGATGGACGGCGTGGCGCCAC  
GCCCTTATAATACAAAGCATGGCATCGCTTAATAGGAAATTGGAAAGATATA  
TTACCCCCAGAGAGTCAAATGTTAGTAGCGAAACAATTGATTAATATGGAAATCAGAGGT  
GGCTATATAAGTAAAACACAAATTAGGGCACAGGCAAGTCCGAGAAACAGTATGT  
CCAGGACAAGCGTTATGAGGAGATCCAAACGTGGCCCCACTTACAGAAATCCACT  
CTGGAGATTGTCGAGACGTTCCGTTCCCTAGACAAAGAACATGTTAACCTGATCCT  
AGAGAGGAATTGATGCCAGATTATCATTGAAAATAATCAAGTACGAAGACGGAGTTCT  
ATAAAATAAGAATAAATTACACTGAGTTCAAGTCAGTCAAGTCAAGTCAAGTCAAGT  
TATATGTTCTCAGAAAAGTACTTACAAATTGATAGTATAGTGAATAAGCCGC

TTAACAAATGTTTATATAACATTCTAAATTATGTTTAAATAATTGTTGTAACCATTCT  
ATCTT

**>Slinearis\_PGRP-LBe2 TRINITY\_DN65546\_c3\_g3\_i5 len=1310**

AAGGTAGTCACACCGTACACTTTTCTATCGAGCTAAAACGATCTGGAGTCCTCC  
AATAATCTTGAAAGTATTGAAGGTTATTTAAACATTAAATGTCATTTGAATCT  
CCACAGACAGGCTCAAGGACTTCACCATATCCTTTAGAAATATCTCAAGACTGTACCG  
CAGGTAATCCAAACGCTTAGAAAAAACTCTATGTGTGGCTACATTATATCTTCGAG  
AACCAATCGAAGTCGCCGAATTACAGGAAATTTCATTTATTTCATCGAGTGTGATA  
AAAATAATCTATTTAATAAAAATAATCATAATCTGAAACAGTTTCTATAATCGTACC  
TAATAACAATCTACAAGCTACCTAGAGTAGTTAGTTGAAAAAGTTAAATTTTAAT  
TTAGAAATACCCACGATGATTAATTATTTGCTGTTATGTTATTTAATGTTGTG  
AACAGTTCGTATATCCGACCCCTGAAATTGTTACGAGGGAGGAATGGTGCAGAAAACCG  
CCCACATCCGTTGAGAAATTAACCTACCCGTCCTACGTTGTCATACACCACAGTTAT  
ATACCTGCAGCTGTTACAACAAGGAGGAATGTATAATGCAATGCAATGGATGCAAAG  
TTTCATCAACAAAATCGCTCATGGTGCATATTGGATACAATTCGCTGTTGGAGGGAT  
AACAGAAATATACGTGGGAAGGGGATGGACGGCCGTGGCGCCCACGCCCCCTTATAAT  
ACCAAAAGCATGGGCATCGTCTAATAGGAAATTGGGAAGATATATTACCCCCAGAGAGT  
CAAATGTTAGTAGCGAAACAATTGATTAATATGGGAATCAGAGGTGGCTATATAAGTAAA  
AACTACAAATTAAATTGGGCACAGGCAAGTCCGAGAAACAGTATGTCCAGGACAAGCGTTA  
TATGAGGAGATCCAAACGTGGCCCCACTTACAGAAAATCCCACCTGGAGATTGTCGA  
GACGTTCCCGTTCCCTAGACAAAGAACATGTTAACCTGATCCTAGAGAGGAATTGAT  
GCCAGATTATCATTGAAAATAATCAAGTACGAAGACGGAGTTCTATAAATAAGAATAA  
ATTTACACTGAGTTCAAGTCAGTGTGTTGTATAACACAAATATGTATATGTTCTCAGAA  
AAAGTACTTACAAATTGATATAGTATAGTTGAATAATAAGCCGCTAACATGTTATA  
TAACATTCTAAATTATGTTAAATAATTGTTGTAACCATTCTATCTT

## Supplementary references

1. Sievers, F. *et al.* (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol. Syst. Biol.* *7*, 539–539.
2. Vallier, A., Vincent-Monégat, C., Laurençon, A., and Heddi, A. (2009). RNAi in the cereal weevil *Sitophilus* spp: systemic gene knockdown in the bacteriome tissue. *BMC Biotechnol.* *9*, 44.
3. Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* *17*, 10.
4. Grabherr, M.G. *et al.* (2011). Full-length transcriptome assembly from RNA-Seq data without a reference genome. *Nat. Biotechnol.* *29*, 644–652.
5. Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment search tool. *J. Mol. Biol.* *215*, 403–410.
6. Vigneron, A. *et al.* (2014). Insects recycle endosymbionts when the benefit is over. *Curr. Biol.* *24*, 2267–73.
7. Balmand, S., Lohs, C., Aksoy, S., and Heddi, A. (2013). Tissue distribution and transmission routes for the tsetse fly endosymbionts. *J. Invertebr. Pathol.* *112 Suppl*, S116–22.
8. Singh, S.R., Liu, W., and Hou, S.X. (2007). The adult *Drosophila* malpighian tubules are maintained by multipotent stem cells. *Cell Stem Cell* *1*, 191–203.
9. Anselme, C. *et al.* (2008). Identification of the weevil immune genes and their expression in the bacteriome tissue. *BMC Biol.* *6*, 43.
10. Vigneron, A. *et al.* (2012). Host gene response to endosymbiont and pathogen in the cereal weevil *Sitophilus oryzae*. *BMC Microbiol.* *12 Suppl 1*, S14.
11. Maire, J., Vincent-Monégat, C., Masson, F., Zaidman-Rémy, A., and Heddi, A. (2018). An IMD-like pathway mediates both endosymbiont control and host immunity in the cereal weevil *Sitophilus* spp. *Microbiome* *6*, 6.
12. Masson, F. *et al.* (2015). Weevil endosymbiont dynamics is associated with a clamping of immunity. *BMC Genomics* *16*, 819.
13. Lemaitre, B., and Hoffmann, J. (2007). The Host Defense of *Drosophila melanogaster*. *Annu. Rev. Immunol.* *25*, 697–743.